AJCN Tufts Nutrition Symposium, Boston Sept 24-26
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fleming, D. J
Right arrow Articles by Wood, R. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fleming, D. J
Right arrow Articles by Wood, R. J
Agricola
Right arrow Articles by Fleming, D. J
Right arrow Articles by Wood, R. J
American Journal of Clinical Nutrition, Vol. 74, No. 2, 219-226, August 2001
© 2001 American Society for Clinical Nutrition

Original Research Communication

Aspirin intake and the use of serum ferritin as a measure of iron status1,2,3,4

Diana J Fleming1, Paul F Jacques1, Joseph M Massaro1, Ralph B D'Agostino, Sr1, Peter WF Wilson1 and Richard J Wood1

1 From the Mineral Bioavailability Laboratory and the Epidemiology Program, Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston; The Framingham Heart Study, Framingham, MA; and Boston University Schools of Medicine and Public Health and Department of Mathematics and Statistics.

2 The contents of this publication do not necessarily reflect the views or policies of the US Department of Agriculture, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government.

3 Supported in part by the National Livestock and Meat Board; US Department of Agriculture contract no. 53-3K06-5-10; National Institutes of Health contract N01-HC-38038; National Heart, Lung and Blood Institute grant no. R01-HL-40423-05; and National Institute of Neurological Disorders and Stroke grant no. 2-R01-NS-17950-12.

4 Address reprint requests to RJ Wood, Mineral Bioavailability Laboratory, JM-USDA-HNRCA, 711 Washington Street, Boston, MA 02111. E-mail: rwood{at}hnrc.tufts.edu.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Background: Atherosclerosis, a primary cause of myocardial infarction (MI), is an inflammatory disease. Aspirin use lowers risk of MI, probably through antithrombotic and antiinflammatory effects. Because serum ferritin (SF) can be elevated spuriously by inflammation, reported associations between elevated SF, used as an indicator of iron stores, and heart disease could be confounded by occult inflammation and aspirin use if they affect SF independently of iron status.

Objective: We tested the hypothesis that aspirin use is associated with reduced SF.

Design: We used analysis of covariance to investigate the relation between SF and categories of aspirin use in 913 elderly participants aged 67–96 y in the Framingham Heart Study.

Results: After adjustment for sex, age, body mass index, smoking, alcohol use, concentrations of C-reactive protein and liver enzymes, white blood cell count, and use of nonaspirin nonsteroidal antiinflammatory drugs and other medications, subjects who took >7 aspirins/wk had a significantly lower (by 25%) geometric mean SF than did nonusers, who took <1 aspirin/wk (71 compared with 95 µg/L, respectively; P for trend = 0.004). This effect of aspirin on SF was more marked in diseased subjects than in healthy subjects (mean SF was 50% lower compared with 21% lower, respectively).

Conclusions: Aspirin use is associated with lower SF. We suggest this effect results from possible increased occult blood loss and a cytokine-mediated effect on SF in subjects with inflammation, infection, or liver disease. The relations between aspirin, inflammation, and SF may confound epidemiologic associations between elevated SF, as an indicator of iron stores, and heart disease risk.

Key Words: Aspirin • serum ferritin • myocardial infarction • elderly • cytokine • C-reactive protein • inflammation • iron stores • epidemiology • atherosclerosis • antiinflammatory


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
It was suggested that elevated body iron stores are a risk factor for heart disease (1, 2). This idea was supported by the results of 2 prospective studies showing that subjects with moderate serum ferritin (SF) concentrations (>=200 µg/L) had an {approx}2-fold greater factor-adjusted risk of acute myocardial infarction (MI) than did subjects with SF <200 µg/L (3, 4). However, this association between elevated iron stores and heart disease is controversial because it was not found in 4 other prospective studies that also used SF as a measure of iron stores (5–9). SF is a commonly used measure of iron status that accurately reflects total body iron stores under most circumstances (10–13). However, a major drawback to its use in estimating body iron stores is that ferritin synthesis and secretion by hepatic cells can be increased by inflammatory cytokines (14), which could result in increased blood SF concentrations that do not reflect actual increases in iron stores.

It is currently believed that aspirin plays a pivotal role in the pathogenesis of heart disease (15, 16). Aspirin is a commonly used over-the-counter medication that lowered the risk of a first MI in subjects enrolled in a large clinical trial (17). Independent of its action in lowering heart disease risk, aspirin may also reduce body iron stores because of increased risk of bleeding, a well-known adverse effect associated with its use (18–23). Three studies investigated changes in hemoglobin concentrations in conjunction with aspirin use, but the results of these studies were inconclusive (24–26). Although 2 of these studies (24, 25) found an apparent decrease in hemoglobin concentration in aspirin-treated subjects, mean hemoglobin concentrations remained within the normal reference range during the limited period of observation in these iron-replete subjects. Furthermore, hemoglobin concentration is the last iron index to change in uncomplicated iron deficiency, and thus it may not provide information about early stages of iron storage depletion, which instead is reflected by decreased SF concentration. A possible adverse effect of aspirin use on body iron stores was suggested recently by a study of Danish men aged 40–70 y; aspirin users had significantly lower SF than did nonusers (27). However, in that study, other factors that might influence SF concentrations were not addressed.

Thus, we undertook the analyses described in this article to test the hypothesis that regular aspirin users among the elderly men and women in the Framingham Heart Study cohort have significantly lower SF concentrations than do nonusers of aspirin. In this analysis we controlled for potential confounding influences of chronic diseases and use of other medications known to affect blood measures of iron status.


   SUBJECTS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Study population
The Framingham Heart Study is a longitudinal study of heart disease risk factors that was begun in 1948–1950 and is described in detail elsewhere (28). The procedures and protocols of the study were approved by the Institutional Review Board for Human Research at Boston Medical Center. The study population originally consisted of 5127 men and women aged 30–62 y who were selected largely at random from residents of Framingham, MA. Data collected in the study have included demographics, an extensive medical history including personal habits, a detailed physical examination, and various clinical and biochemical indexes. Subjects were invited for follow-up examinations every 2 y to screen for the development of disease and to measure changes in clinical, biochemical, and behavioral variables.

A total of 1401 surviving members of the original cohort, now aged 67–96 y, participated in cycle 20 of data collection between February 1988 and January 1990. All materials and data used for the present analysis were collected at the cycle 20 examination. Serum samples were not sufficient for measuring either C reactive protein (CRP) or iron indexes for 385 subjects, and 55 persons were missing information on aspirin use, so the sample size was reduced to 961. The rationale and sequence for exclusions are described below and resulted in a final reduction of the sample to 913 subjects.

Biochemical indexes
Blood samples were collected from nonfasting subjects by venipuncture into evacuated EDTA-coated tubes. One day after collection, the samples were received at the Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, where clinical chemistry analyses were performed. Serum aliquots were stored in trace-mineral-free Nunc vials (Nalge Nunc International Corp, Naperville, IL) at -20°C.

SF concentration was measured by using the Magic Ferritin 125I radioimmunoassay (Ciba Corning, Norwood, MA). In our laboratory, assay of the World Health Organization International Ferritin Standard 80/578 with this radioimmunoassay yielded mean ferritin values that were within 5–10% of the stated concentrations of this quality control. The rate of degradation of ferritin in specimens stored at -20°C is <0.3%/y (29). Because the Framingham cycle 20 serum samples were stored at -20°C for 3–5 y before we assayed for ferritin, this translates into a small practical effect (0.9–1.5%) on the original values.

CRP, which is used as an inflammatory index (30, 31), was measured by using an immunoturbidimetric method with a CRP SPQ Test System Antibody Reagent Set II (INCSTAR, Stillwater, MN) on a Cobas Fara II Centrifugal Analyzer (Roche, Nutley, NJ). Because the detection limit of our CRP assay was 6 mg/L, we defined inflammation as a CRP concentration >=6 mg/L. Recently, ultrasensitive CRP assays with detection limits as low as 0.05 mg/L were developed; these assays can detect low-grade inflammation (30, 32). Because our detection limit was 6 mg CRP/L, we clearly missed identifying those subjects with mild inflammation.

Concentrations of the liver enzymes alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase were measured by using an in vitro diagnostic reagent system (Roche) on a Cobas Fara II Centrifugal Analyzer (Roche). A System 9000 Diff Model Automated Cell Counter (Serono-Baker Diagnostics Inc, Allentown, PA) was used to measure white blood cell count in whole blood samples.

Exclusions
Blood ferritin concentrations can be elevated in conditions of pathologic iron overload. The most common inherited form is hereditary hemochromatosis, an autosomal recessive disorder characterized by increased iron absorption that affects {approx}1 in 300 persons in populations of northern European descent (33). We identified those subjects with the highest probability of being homozygous for hemochromatosis as those with all 3 of the following abnormal iron indexes: SF >300 µg/L, serum iron >32 µmol/L (180 µg/dL), and transferrin saturation >0.50 (50%) (34, 35). Three individuals met these criteria and were excluded from our analyses. Various heterozygous genotypes for the HFE gene can influence iron stores (36–38). Because we did not analyze the genotypes of the subjects, the effect of these heterozygous genotypes on SF in this population is unknown. An additional female subject with a SF concentration of 934 µg/L was excluded because she had unusually high values for hemoglobin (203 g/L), hematocrit (0.59, or 59%), and red blood cell count (6.7 x 1012/L, or 6.7 x 106/mm3). She may have had polycythemia vera, a neoplastic stem cell disorder of unknown cause. Associated primarily with excessive proliferation of red blood cell precursors, it is typically characterized by elevated hemoglobin and hematocrit with or without an abnormal red blood cell count (39).

Anemia of chronic disease (ACD) is a mild to moderate form of anemia that is hypochromic and often microcytic. ACD accompanies most acute and chronic conditions involving inflammation, infection, liver disease, and malignancy (30, 31, 40–43). It is characterized by both impaired iron metabolism and impaired erythropoiesis. Although the precise mechanisms underlying ACD are still unknown, research suggests that both aspects of its pathogenesis are cytokine mediated (40–43). ACD generally mimics the hematologic profile of iron deficiency anemia, except that it involves a normal or elevated SF concentration in contrast with the decreased SF observed in uncomplicated iron deficiency (40–44). The increased SF concentration results from the fact that ferritin is a positive acute-phase protein whose synthesis and secretion by hepatic cells are increased by inflammatory cytokines (14). Thus, although SF typically reflects body iron stores (10–13, 45), during various diseases and conditions including malignancy (30, 31) it becomes an unreliable indicator of iron status because its blood concentrations become disproportionately elevated compared with actual iron stores (42–44, 46). Because of the many different types of cancer and the potentially varying, unknown effects of different malignancies on SF concentrations, we excluded subjects with active cancer at exam 20 (n = 53; 5%) from our analyses.

Data analysis
To collect data about aspirin use, we asked subjects the question "Number of aspirins per week?" Their responses were classified into 4 categories: nonusers (<1 aspirin/wk; n = 609; 66.7%), 1–6 aspirins/wk (n = 90; 9.9%), 7 aspirins/wk (n = 131; 14.3%), and >7 aspirins/wk (n = 83; 9.1%). Information about the dose of aspirin used was not obtained. We assumed that our elderly subjects used the commonly available standard-dose adult aspirin containing {approx}325 mg acetylsalicylic acid/tablet.

Our analysis included several covariates previously shown to be associated with SF. Ferritin concentrations are higher in men (47) and are positively associated with age (47) and alcohol intake (48–52). Age was included in the model as a continuous variable. For alcohol, subjects were asked to respond either yes or no to whether they had consumed any type of alcoholic beverage during the past year. Body mass index (BMI) was also included in our model because previously we found that SF concentrations were positively correlated with body size as measured by BMI in this population (53). Smoking status during the past year was included in the model because of its possible influence on iron stores (49). The smoking variable was created as a yes-or-no variable and included cigarette, pipe, and cigar smokers.

Iron stores are also influenced by excess blood loss (54). Therefore, we adjusted for the potential confounding effects of various medications other than aspirin that are known to increase the possibility of bleeding, although these potential effects have not been shown to be associated with ferritin concentrations. We created a yes-or-no variable for use of medications, within the past year, that are in >=1 of the following 3 categories of drugs known to affect blood loss: antiplatelet medications, anticoagulants, and nonaspirin nonsteroidal antiinflammatory drugs (NSAID). Information on use of these 3 categories of drugs was missing for 4, 6, and 3 subjects, respectively, and we classified them as nonusers. Antiulcer medications were also included because although they do not directly increase the risk of bleeding, persons who use them are at increased risk of blood loss resulting from ulcers. One subject with missing information on antiulcer medication use was classified as a nonuser. It is well known that donating blood alters blood measures of iron status and therefore may affect SF concentrations. However, it is unlikely that blood donation affected our results in this elderly sample because until recently US blood banks generally had a maximum donor age of 65 y (55, 56). It is also well known that use of both estrogen and progesterone may cause breakthrough bleeding in postmenopausal women, and thus may be a potential confounder of SF values in our elderly female subjects. We consider this to be of small practical significance because only 24 women (4%) reported current estrogen use and <1% of women reported current progesterone use. We suggest 2 reasons for the small number of women reporting current estrogen use. First, the data were collected 10–12 y ago when hormone replacement therapy was not as widely advocated and practiced as it is today. Second, the women in this population were elderly, with a mean age of {approx}75 y. It may be that more of the women had used estrogen but had stopped using it many years before the cycle 20 exam.

Because acute or chronic inflammation, infection, and liver disease are potential confounders of SF as an indicator of iron stores, as discussed above, we controlled for the possible confounding effects of these disease conditions by creating yes-or-no variables on the basis of the following disease criteria. Inflammation was defined as a CRP concentration >=6 mg/L, the detection limit of the laboratory method used at cycle 20. Infection was defined as a white blood cell count above or below the normal range (men: 3.9–10.6 x 109/L; women: 3.5–11.0 x 109/L). Possible liver disease was defined as an abnormal elevation of any 1 of 3 liver enzymes. The 3 enzymes and the definitions of abnormal elevation were alanine aminotransferase >2 times the upper limit of normal (>1.23 µkat/L, or >74 U/L), aspartate aminotransferase >2 times the upper limit of normal (>1.13 µkat/L, or >68 U/L), and alkaline phosphatase >1.5 times the upper limit of normal (>2.58 µkat/L, or >154.5 U/L). These disease criteria were intended to be suggestive, not diagnostic.

All statistical procedures were performed by using SAS for WINDOWS, version 6.12 (57). P < 0.05 was considered statistically significant. Analysis of covariance was carried out in PROC GLM to investigate the relation between iron stores, as measured by SF concentrations, and categories of aspirin use with adjustment for the above-mentioned covariates. Pairwise comparisons were performed after the overall F was found to be statistically significant. Because the distribution of SF values was positively skewed, a natural logarithmic transformation was applied to the measurements before the analysis. Consequently, we present geometric mean SF concentrations. A test for linear trend across the 4 aspirin categories was performed.

To examine the possibility of effect modification by disease regarding the association between SF and aspirin use, we did the following: 1) tested for an interaction between inflammation and aspirin use on SF, 2) combined subjects with infection and liver disease into one group and tested the interaction with aspirin use on SF, and 3) combined the 3 disease conditions into 1 variable representing those subjects whose SF may be falsely elevated because of an underlying disease condition (defined as the diseased group) and tested its interaction with aspirin use on SF. Although an elderly population will not be absolutely free of disease, we defined the rest of the population as the normal group. Nine individuals were missing data on white blood cell count; we classified these subjects as normal because of the low prevalence (4%) of an abnormal white blood cell count in this population.

Differences between the normal and diseased groups with respect to subject characteristics and SF were compared by using the Student's t test for continuous variables and by chi-square analysis (or Fisher's exact test when >=25% of expected cell counts were <5) for nominal categorical variables. Means and prevalence estimates were determined on the basis of nonmissing data. Missing values included 73 for BMI (56 and 17 in the normal and diseased groups, respectively), 2 for alcohol use in the normal group, 4 for use of antiplatelet medications (3 and 1 in the normal and diseased groups, respectively), 3 for use of NSAID (2 and 1 in the normal and diseased groups, respectively), and 6 for use of anticoagulant agents (4 and 2 in the normal and diseased groups, respectively). In an effort to further examine any significant interaction between disease and aspirin use on SF concentrations, we calculated the difference in adjusted mean SF concentrations between the normal and diseased groups for each aspirin-use category.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Characteristics of the total sample
Characteristics of our study population are shown in Table 1Go. Fifty-one percent of subjects used medications associated with risk of increased blood loss (aspirin, nonaspirin NSAID, antiplatelet drugs, and anticoagulants) or medications used to treat conditions involving risk of blood loss (antiulcer agents). Of these subjects, 81.5% used a medication from 1 of the drug categories, 16.7% used medications from 2 categories, 1.5% used medications from 3 categories, and 1 subject used medications from 4 categories. In our population, 6.5% (n = 59 of 913) had an inflammatory condition, 3.7% (n = 34 of 913) had abnormally elevated liver enzymes, and 4.2% (n = 38 of 903) had an infection. Of these 131 subjects, 88.5% (n = 116) had 1 condition, 4.5% (n = 6) had 2 conditions, and 0.8% (n = 1) had 3 conditions. Thus, 13.5% (n = 123) of the total sample composed the diseased group. The SF concentrations of these subjects were likely to be elevated, disproportionate to actual iron stores, as a result of underlying disease conditions. In the total sample, men had a significantly higher geometric mean SF (112.7 µg/L; 95% CI: 102.3, 124.1) than did women (74.7 µg/L; 95 % CI: 69.0, 80.8; P < 0.0001).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Characterstics of subjects in the normal and diseased groups1
 
Aspirin use and mean SF concentrations in the total population
The results of the analysis of covariance for aspirin use and SF in the total population are shown in Table 2Go. After adjustment for sex, age, BMI, smoking status, alcohol intake, use of nonaspirin NSAID and other medications associated with blood loss, inflammation, infection, and possible liver disease, those who used >7 aspirins/wk had a significantly lower (by 25%) mean SF (71 µg/L; 95% CI: 57, 87) than did nonusers of aspirin (95 µg/L; 95% CI: 88, 103). There was a highly significant, inverse linear trend between aspirin use and SF (P = 0.004). Adjustment for covariates had little effect on the association between aspirin use and SF (data without adjustment for covariates are not shown). The 3 possible interactions between aspirin use and 1) inflammation, 2) infection and liver disease combined, and 3) inflammation, infection, and liver disease combined (ie, the diseased group) were not significant. However, the interaction between the diseased group and aspirin use was marginally significant (P = 0.07). This prompted us to examine the relation between SF and aspirin use in the normal and diseased groups separately.


View this table:
[in this window]
[in a new window]
  		TABLE 2. Serum ferritin concentrations by category of usual aspirin use1
 
Comparison of characteristics between the normal and diseased groups
As shown in Table 1Go, there were no significant differences between the normal and diseased groups in the proportions of men and women or the percentages of subjects who were smokers, alcohol users, or users of aspirin, nonaspirin NSAID, antiulcer medications, antiplatelet drugs, or anticoagulants. Furthermore, mean age and BMI did not differ significantly between the groups. The range of aspirin intake was 1–56 aspirins/wk in the normal group and 1–84/wk in the diseased group. Median aspirin intake in the category of subjects who took >7 aspirins/wk was the same for both groups: 14 aspirins/wk, or 2/d. The diseased group had a higher geometric mean SF concentration than did the normal group (97 and 87 µg/L, respectively), but this difference was not significant.

Aspirin use and mean SF concentrations in the normal and diseased groups
There was an inverse association between SF concentration and aspirin intake in both the normal group and the diseased group; the relation was stronger in the diseased group (Figure 1Go, A and B; Table 2Go). In the normal group, there was a marginally significant difference (P = 0.06) between the adjusted mean SF values of 65 µg/L in the >7 aspirins/wk category and 82 µg/L in the nonusers category; the former mean value is 21% lower than the latter. Also in the normal group, the adjusted mean SF concentrations in the 1–6 aspirins/wk and 7 aspirins/wk categories (78 and 75 µg/L, respectively) were not significantly different from the mean for nonusers. In the diseased group, those using >7 aspirins/wk had a significantly lower (by 50%) adjusted mean SF concentration than did the nonusers (59 compared with 119 µg/L, respectively; P = 0.02). In addition, there was a marginally significant difference (P = 0.06) between the mean SF of subjects using 7 aspirins/wk (74 µg/L) and that of the nonusers.




View larger version (26K):
[in this window]
[in a new window]
  		FIGURE 1. Adjusted geometric mean serum ferritin concentrations (with 95% CI) by category of usual aspirin intake for the normal group (n = 790; A) and the diseased group (n = 123; B). The means were adjusted for sex, age, BMI, smoking status, alcohol use, and use of antiulcer, antiplatelet, anticoagulant, and nonaspirin nonsteroidal antiinflammatory medications. The median number of aspirins used by the subjects in each aspirin-intake category are plotted on the x axis for each group. These medians are the same for the normal and diseased groups in all aspirin-intake categories except for the category of 1–6 aspirins/wk. The medians are as follows: for nonusers (<1 aspirin/wk), 0 aspirins; for 1–6 aspirins/wk, 3 aspirins for normal group and 3.5 aspirins for diseased group; for 7 aspirins/wk, 7 aspirins; and for >7 aspirins/wk, 14 aspirins.

 
Differences in adjusted mean SF concentrations between the normal and diseased groups for each aspirin-use category are shown in Table 2Go; for nonusers, this difference was –37 µg/L (normal - diseased group). In contrast, the difference for the highest aspirin-intake category, >7 aspirins/wk, was only 6 µg/L.

Because older persons are more likely to use multiple NSAID and to develop gastrointestinal bleeding as a result of NSAID use (22), we tested for an interaction between the effects of aspirin use and those of nonaspirin NSAID use on SF concentration. No significant interaction was found.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
These findings clearly show an inverse association between aspirin use and SF concentrations in the free-living, elderly Framingham Heart Study cohort. Our results are consistent with those of Milman et al (27), who found that among 1146 Danish men aged 40–70 y who were not blood donors, those taking aspirin (n = 170) had significantly lower median SF concentrations than did aspirin nonusers (136 and 169 µg/L, respectively). However, 57% of the aspirin users took the standard dose of aspirin used in Denmark, 1–3 g acetylsalicylic acid/d, which is 3–9 times the standard US dose of 325 mg. Because it is well known that aspirin's adverse effects with regard to blood loss are dose dependent, the lower SF observed in Danish aspirin users could be a result of increased blood loss associated with use of high doses of aspirin, and thus may not be observed in other populations. Moreover, no attempt was made by the investigators to account for potential influences on SF other than aspirin. Our data from this US population extend the observations of Milman et al (27) by examining the association between SF and categories of aspirin intake in elderly men and women while controlling for potential confounding factors, such as age (47), BMI (53), smoking status (49), alcohol intake (48–52), use of other medications associated with increased risk of bleeding, hemochromatosis (33), inflammation, infection, and possible liver disease (31, 40, 42, 43).

An obvious explanation for the observed inverse association between aspirin use and SF concentration could be lower body iron stores resulting from increased occult blood loss (not measured in this study) associated with aspirin use. The increased risk of blood loss in aspirin users results from the 2 well-known, major side effects of aspirin: gastrointestinal irritation and an increased bleeding tendency (18, 20–22, 58–60).

The inverse association between aspirin intake and SF concentration that we observed in the total population was much stronger in the subgroup of diseased elderly subjects with underlying inflammation, infection, liver disease, or more than one of these conditions than in the rest of the population, or normal group (Figure 1Go, B compared with A, respectively). A simple explanation for the stronger inverse association in the diseased group than in the normal group cannot be found in either differences in subject characteristics or patterns of aspirin use. We propose a cytokine-mediated mechanism that does not involve blood loss to explain this relation between aspirin use and SF. First, in those elderly subjects who did not use aspirin, the 45% higher adjusted mean SF concentration in the diseased group than in the normal group most likely reflects spuriously elevated SF concentrations resulting from underlying pathology. That is, because of the presence of disease, blood ferritin concentrations were likely increased as a result of cytokine-mediated synthesis and secretion of ferritin from the liver, and thus it is unlikely that these SF concentrations reflected higher iron stores. Second, the minimal difference in adjusted mean SF concentrations between the diseased and normal groups among aspirin users is consistent with a lowering of cytokine-elevated SF concentrations in the diseased group subsequent to the antiinflammatory effect of aspirin. We speculate that in the diseased group, aspirin intake was sufficient to decrease the presence of inflammation and inflammatory cytokines in the body, reducing blood ferritin concentrations that had been elevated previously in an iron-independent manner via cytokine-induced ferritin gene expression (14). In our cohort, this idea was supported by additional analyses (data not shown) indicating that among those individuals in the diseased group who had a detectable CRP concentration (>=6 mg/L), the geometric mean CRP of aspirin users was significantly lower than that of subjects who did not use aspirin (8.9 compared with 12 mg/L; P = 0.05, Student's t test). Furthermore, of all the elderly subjects with an elevated CRP concentration (n = 59), those individuals with CRP values >=10 mg/L, the median value for the group, had a nonsignificantly higher geometric mean SF (117 µg/L) than did those subjects with CRP values below the median (86 µg/L). Although these limited observations provide only weakly suggestive evidence of an antiinflammatory effect of aspirin that subsequently might reduce cytokine-induced elevations in SF concentrations, one recently published report from a clinical trial supports this notion. Ikonomidis et al (61) investigated the effects of a 300-mg daily dose of aspirin on cytokines and CRP in a 6-wk randomized, double-blind, placebo-controlled crossover trial in 40 patients (mean age 55 y) with atherosclerotic disease and clinically stable angina. The authors observed that after 6 wk of aspirin administration, there were significant reductions in proinflammatory cytokine (interleukin 6, or IL-6) and CRP concentrations in plasma. Interestingly, the authors speculated that "the reduction of CRP by aspirin is likely secondary to the reduction in IL-6, because IL-6 is known to stimulate the synthesis of acute phase proteins by the liver." Because ferritin is also a positive acute phase protein (31), we suggest that the reduction of circulating proinflammatory cytokines by aspirin would also result in a reduction in plasma ferritin concentrations that had been elevated previously because of underlying inflammatory processes rather than higher iron stores.

Thus, we believe that the observed inverse association between SF concentration and aspirin use is likely a result of the combined effects of 2 processes: 1) a probable lowering of body iron stores resulting from increased occult blood loss in chronic aspirin users, and 2) a less obvious mechanism involving a differential reduction in SF concentrations in diseased subjects because of the antiinflammatory action of aspirin on cytokine-induced ferritin production.

We believe that the inverse association between aspirin intake and SF concentration has implications for epidemiologic studies investigating the relation between elevated body iron stores and risk of heart disease, and possibly other chronic diseases for which underlying chronic inflammation is a pathogenic factor. First, as illustrated in Figure 2AGo, we suggest that inflammation is likely a true confounder of the association between elevated iron stores and risk of MI. It is now widely accepted that atherosclerosis, the principal contributor to the pathogenesis of MI, is an inflammatory disease—a response to injury of the vascular endothelium (16). Independent of its involvement in MI risk, inflammation also increases the blood concentration of ferritin as a positive acute phase protein, as previously discussed (14). Because the chronic, low-grade inflammation of atherosclerosis may be present throughout a person's lifetime (16), and therefore years before symptomatic coronary heart disease, we believe that the SF concentrations in epidemiologic studies investigating the association between elevated iron stores and risk of MI could be confounded by being spuriously elevated because of the chronic, mild inflammation of atherosclerosis, other inflammatory diseases, or both. This could occur even if the studies excluded prevalent cases of heart disease or individuals with a history of cardiovascular disease.



View larger version (12K):
[in this window]
[in a new window]
  		FIGURE 2. A: Proposed relation between inflammation, serum ferritin (SF), and risk of myocardial infarction (MI). B: Proposed relation between aspirin use, inflammation, SF, and risk of MI. Solid lines indicate relations supported by research results. Dashed lines indicate putative relations.

 
Second, the inverse association that we observed between aspirin intake and SF concentration suggests that in study populations in which aspirin use is common, aspirin may be an important confounder of the association between elevated iron stores, as measured by SF, and risk of MI (Figure 2BGo) because aspirin use is associated independently with both decreased SF (Figure 1Go) and decreased risk of MI (17, 62). Aspirin may lower SF concentrations through both blood loss and its antiinflammatory action. Thus, because aspirin users are more likely to have lower SF concentrations and a lower risk of heart disease, SF concentrations and risk of MI would be noncausally linked through the complex effects of aspirin on SF. Consequently, an association between moderately elevated SF concentrations and increased risk of MI could be observed in some study populations because of spuriously elevated SF concentrations as a result of underlying inflammation (from atherosclerosis or other processes); these SF values would not truly reflect higher iron stores.

In conclusion, our study clearly shows that aspirin use in elderly Americans is associated with lower SF concentrations. It is uncertain whether these reduced SF concentrations actually indicate lower body iron stores because of the antiinflammatory effects of aspirin and the fact that ferritin is an acute phase protein whose blood concentration is influenced by proinflammatory cytokines. We suggest that one possible way to eliminate potential confounding by aspirin use in epidemiologic studies of SF and chronic disease is to include only those subjects with an undetectable CRP as determined by an ultrasensitive CRP assay. To our knowledge, this has not been done in any of the prospective studies examining the association between elevated SF concentrations and risk of MI (3–9).


   ACKNOWLEDGMENTS
 
We thank Irwin Rosenberg and Gerard E Dallal of Tufts University for their inspiration and encouragement in investigating this topic. We also thank the Nutrition Evaluation Laboratory at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University for their invaluable biochemical analyses.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981;1:1293–4.[Medline]
  2. Sullivan JL. The iron paradigm of ischaemic heart disease. Am Heart J 1989;117:1177–88.[Medline]
  3. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992; 86:803–11.[Abstract/Free Full Text]
  4. Klipstein-Grobusch K, Koster JF, Grobbee DE, et al. Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr 1999;69:1231–6.[Abstract/Free Full Text]
  5. Manttari M, Manninen V, Huttunen JK, et al. Serum ferritin and ceruloplasmin as coronary risk factors. Eur Heart J 1994;15:1599–603.[Abstract/Free Full Text]
  6. Stampfer MJ, Grodstein F, Rosenberg I, Willett W, Hennekens C. A prospective study of plasma ferritin and risk of myocardial infarction of US physicians. Circulation 1993;87:688 (abstr).
  7. Ma J, Grodstein F, Rifai N, Rosenberg I, Hennekens CH, Stampfer MJ. Plasma ferritin levels and future risk of myocardial infarction and ischemic stroke in US physicians. Am J Epidemiol 1999; 149:S74 (abstr).
  8. Frey GH, Krider DW. Serum ferritin and myocardial infarction. W V Med J 1994;90:13–5.[Medline]
  9. Magnusson MK, Sigfusson N, Sigvaldason H, Johannesson GM, Magnusson S, Thorgeirsson G. Low iron-binding capacity as a risk factor for myocardial infarction. Circulation 1994;89:102–8.[Abstract/Free Full Text]
  10. Cook JD, Lipschitz DA, Miles LE, Finch CA. Serum ferritin as a measure of iron stores in normal subjects. Am J Clin Nutr 1974;27: 681–7.[Abstract]
  11. Bezwoda WR, Bothwell TH, Torrance JD, et al. The relationship between marrow iron stores, plasma ferritin concentrations and iron absorption. Scand J Haematol 1979;22:113–20.[Medline]
  12. Walters GO, Miller FM, Worwood M. Serum ferritin concentration and iron stores in normal subjects. J Clin Pathol 1973;26:770–2.[Abstract/Free Full Text]
  13. Lipschitz DA, Cook JD, Finch CA. A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med 1974;290:1213–6.
  14. Tran TN, Eubanks SK, Schaffer KJ, Zhou CY, Linder MC. Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood 1997;90:4979–86.[Abstract/Free Full Text]
  15. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801–9.[Medline]
  16. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999;340:115–26.[Free Full Text]
  17. The Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129–35.[Abstract]
  18. Schror K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997;23:349–56.[Medline]
  19. Willard JE, Lange RA, Hillis LD. The use of aspirin in ischemic heart disease. N Engl J Med 1992;327:175–81.[Medline]
  20. Patrono C. Asprin as an antiplatelet drug. N Engl J Med 1994;330: 1287–93.[Free Full Text]
  21. Dickinson JP, Prentice CRM. Aspirin: benefit and risk in thromboprophylaxis. Q J Med 1998;91:523–38.[Abstract/Free Full Text]
  22. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340: 1888–99.[Free Full Text]
  23. Hawkey CJ. Review article: aspirin and gastrointestinal bleeding. Aliment Pharmacol Ther 1994;8:141–6.[Medline]
  24. Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 1993;54:84–9.[Medline]
  25. Leibovici A, Nachshon L, Wainstok S, Herman J, Greene VW. Low-dose acetylsalicylic acid use and hemoglobin levels. Effects in a primary care population. Can Fam Physician 1995;41:64–8.[Medline]
  26. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309:396–403.[Abstract]
  27. Milman N, Ovesen L, Byg K, Graudal N. Iron status in Danes updated 1994. I: Prevalence of iron deficiency and iron overload in 1332 men aged 40–70 years. Influence of blood donation, alcohol intake, and iron supplementation. Ann Hematol 1999;78:393–400.[Medline]
  28. Dawber TR, Meadors GF, Moore FE. Epidemiological approaches to heart disease: the Framingham study. Am J Public Health 1951; 41:279–86.
  29. Cook JD, Watson SS, Simpson KM, Lipschitz DA, Skikne BS. The effect of high ascorbic acid supplementation on body iron stores. Blood 1984;64:721–6.[Abstract/Free Full Text]
  30. Pepys MB. C-reactive protein fifty years on. Lancet 1981;1:653–7.[Medline]
  31. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448–54.[Free Full Text]
  32. Wilkins J, Gallimore JR, Moore EG, Pepys MB. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem 1998;44:1358–61.[Free Full Text]
  33. Powell LW, Jazwinska E, Halliday JW. Primary iron overload. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron metabolism in health and disease. London: WB Saunders, 1994:227–70.
  34. Fairbanks VF. Laboratory testing for iron status. Hosp Pract (Off Ed) 1991;3(suppl):17–24.
  35. Halliday JW, Powell LW. Iron overload. Semin Hematol 1982;19: 42–53.[Medline]
  36. Garry PJ, Montoya GD, Baumgartner RN, Liang HC, Williams TM, Brodie SG. Impact of HLA-H mutations on iron stores in healthy elderly men and women. Blood Cells Mol Dis 1997;23:277–87.[Medline]
  37. Datz C, Haas T, Rinner H, Sandhofer F, Patsch W, Paulweber B. Heterozygosity for the C282Y mutation in the hemochromatosis gene is associated with increased serum iron, transferrin saturation, and hemoglobin in young women: a protective role against iron deficiency? Clin Chem 1998;44:2429–32.[Abstract/Free Full Text]
  38. Rossi E, Olynyk JK, Cullen DJ, et al. Compound heterozygous hemochromatosis genotype predicts increased iron and erythrocyte indices in women. Clin Chem 2000;46:162–6.[Abstract/Free Full Text]
  39. Fauci AS, Braunwald E, Isselbacher KJ, et al. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill, 1998.
  40. Krantz SB. Pathogenesis and treatment of the anemia of chronic disease. Am J Med Sci 1994;307:353–9.[Medline]
  41. Means RT, Krantz SB. Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood 1991;78:2564–7.[Abstract/Free Full Text]
  42. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992;80:1639–47.[Abstract/Free Full Text]
  43. Means RT. Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells 1995;13:32–7.[Abstract]
  44. Cartwright GE. The anemia of chronic disorders. Semin Hematol 1966;3:351–75.[Medline]
  45. Brink S, Van Schalkwyk DJ. Serum ferritin and mean corpuscular volume as predictors of bone marrow iron stores. S Afr Med J 1982;61:432–4.[Medline]
  46. Yip R, Dallman PR. The roles of inflammation and iron deficiency as causes of anemia. Am J Clin Nutr 1988;48:1295–300.[Abstract/Free Full Text]
  47. Yip R. Changes in iron metabolism with age. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron metabolism in health and disease. London: WB Saunders, 1994:428–48.
  48. Lundin L, Hallgren R, Birgegard G, Wide L. Serum ferritin in alcoholics and the relation to liver damage, iron state and erythropoietic activity. Acta Med Scand 1981;209:327–31.[Medline]
  49. Touitou Y, Proust J, Carayon A, et al. Plasma ferritin in old age. Influence of biological and pathological factors in a large elderly population. Clin Chim Acta 1985;149:37–45.[Medline]
  50. Jacques PF, Sulsky S, Hartz SC, Russell RM. Moderate alcohol intake and nutritional status in nonalcoholic elderly subjects. Am J Clin Nutr 1989;50:875–83.[Abstract/Free Full Text]
  51. Milman N, Kirchhoff M. Relationship between serum ferritin, alcohol intake, and social status in 2235 Danish men and women. Ann Hematol 1996;72:145–51.[Medline]
  52. Leggett BA, Brown NN, Bryant SJ, Duplock L, Powell LW, Halliday JW. Factors affecting the concentrations of ferritin in serum in a healthy Australian population. Clin Chem 1990;36:1350–5.[Abstract/Free Full Text]
  53. Fleming DJ, Jacques PF, Dallal GE, Tucker KL, Wilson PW, Wood RJ. Dietary determinants of iron stores in a free-living elderly population: The Framingham Heart Study. Am J Clin Nutr 1998;67: 722–33.[Abstract]
  54. Fairbanks VF. Iron in medicine and nutrition. In: Shils ME, Olson JA, Shike M, eds. Modern nutrition in health and disease. Philadelphia: Lea & Febiger, 1994:185–213.
  55. Garry PJ, Wayne SJ, Koehler KM, Pathak DR, Baumgartner RN, Simon TL. Prediction of iron absorption based on iron status of female blood donors. Am J Clin Nutr 1992;56:691–8.[Abstract/Free Full Text]
  56. Garry PJ, VanderJagt DJ, Wayne SJ, Koehler KH, Rhyne RL, Simon TL. A prospective study of blood donations in healthy elderly persons. Transfusion 1991;31:686–92.[Medline]
  57. SAS Institute Inc. SAS/STAT user's guide, version 6. 4th ed. Cary, NC: SAS Institute Inc, 1989.
  58. Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989;86:449–58.[Medline]
  59. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointesstianl tract. The double-edged sword. Arthritis Rheum 1995;38:5–18.[Medline]
  60. Daneshmend TK, Sharma HK, Hawthorne AB, Bhaskar NK, Hawkey CJ. A new measure, the gastric bleeding time—prolongation by aspirin in humans. Gastroenterology 1989;96:A108 (abstr).
  61. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999;100:793–8.[Abstract/Free Full Text]
  62. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–9.[Abstract/Free Full Text]
Received for publication April 7, 2000. Accepted for publication November 29, 2000.




This article has been cited by other articles:


Home page
 J. Am. Coll. Nutr.Home page
A.-L. M. Heath, M. A. Roe, S. L. Oyston, A. R. Gray, S. M. Williams, and S. J. Fairweather-Tait
Blood Loss Is a Stronger Predictor of Iron Status in Men Than C282Y Heterozygosity or Diet
J. Am. Coll. Nutr., February 1, 2008; 27(1): 158 - 167.
[Abstract] [Full Text] [PDF]

Home page
 JRSMHome page
J. L Sullivan
The Big Idea: the coxib crisis Iron, aspirin and heart disease risk revisited
J R Soc Med, July 1, 2007; 100(7): 346 - 349.
[Full Text] [PDF]

Home page
 Age AgeingHome page
R. Hammerman-Rozenberg, J. M. Jacobs, D. Azoulay, and J. Stessman
Aspirin prophylaxis and the prevalence of anaemia
Age Ageing, September 1, 2006; 35(5): 514 - 517.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
N. W Solomons and K. Schumann
Intramuscular administration of iron dextran is inappropriate for treatment of moderate pregnancy anemia, both in intervention research on underprivileged women and in routine prenatal care provided by public health services
Am. J. Clinical Nutrition, January 1, 2004; 79(1): 1 - 3.
[Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
J.-M. Liu, S. E Hankinson, M. J Stampfer, N. Rifai, W. C Willett, and J. Ma
Body iron stores and their determinants in healthy postmenopausal US women
Am. J. Clinical Nutrition, December 1, 2003; 78(6): 1160 - 1167.
[Abstract] [Full Text] [PDF]

Home page
 Vasc MedHome page
G. Ramakrishna, T. W Rooke, and L. T Cooper
Iron and peripheral arterial disease: revisiting the iron hypothesis in a different light
Vascular Medicine, August 1, 2003; 8(3): 203 - 210.
[Abstract] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
D. J Fleming, K. L Tucker, P. F Jacques, G. E Dallal, P. W. Wilson, and R. J Wood
Dietary factors associated with the risk of high iron stores in the elderly Framingham Heart Study cohort
Am. J. Clinical Nutrition, December 1, 2002; 76(6): 1375 - 1384.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fleming, D. J
Right arrow Articles by Wood, R. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fleming, D. J
Right arrow Articles by Wood, R. J
Agricola
Right arrow Articles by Fleming, D. J
Right arrow Articles by Wood, R. J

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS